Differences in radiosensitivity between three HER2 overexpressing cell lines

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 35, Issue 6, 2008, Pages 1179-1191

  Steffen, Ann Charlott ^a   Göstring, Lovisa ^b   Tolmachev, Vladimir ^a   Palm, Stig ^c   Stenerlöw, Bo ^a   Carlsson, Jörgen ^a,d  

^a UPPSALA UNIVERSITY   (Sweden)

^b Affibody AB   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

Author keywords

ErbB2; HER2; High LET; Nuclear medicine; Radiation effects; Tumour cells

Indexed keywords

ASTATINE 211; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; CELL LINE; CELL SIZE; CELL SURVIVAL; CONFOCAL MICROSCOPY; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IRRADIATION; PROTEIN EXPRESSION; RADIOSENSITIVITY;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HUMANS; OVARIAN NEOPLASMS; RADIATION DOSAGE; RADIATION TOLERANCE; RECEPTOR, ERBB-2;

EID: 43749086215     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-007-0713-x     Document Type: Article

References (40)

1. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005;23(9):1147-57.
2. DeNardo SJ, DeNardo GL. Targeted radionuclide therapy for solid tumors: an overview. Int J Radiat Oncol Biol Phys 2006;66(2 Suppl):S89-95.
3. Goldenberg DM, Sharkey RM. Advances in cancer therapy with radiolabeled monoclonal antibodies. Q J Nucl Med Mol Imaging 2006;50(4):248-64.
4. O'Donoghue JA, Bardies M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med 1995;36(10):1902-9.
5. Carlsson J, Forssell AE, Hiet-ala SO, Stigbrand T, Tennvall J. Tumour therapy with radionuclides: assessment of progress and problems. Radiother Oncol 2003;66:107-17.
6. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
7. Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 1990;50:4087-91.
8. Gancberg D, Di Leo A, Cardoso F, Rouas G, Pedrocchi M, Paesmans M, et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 2002;13:1036-43.
9. Carlsson J, Nordgren H, Sjostrom J, Wester K, Villman K, Bengtsson NO, et al. HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review. Br J Cancer 2004;90:2344-8.
10. Steel GG. Basic clinical radiobiology. London: Hodder Education; 2002.
11. Hall EJ, Giaccia AJ. Radiobiology for the radiologist. Philadelphia: Lippincott Williams & Wilkins; 2006.
12. Deacon J, Peckham MJ, Steel GG. The radioresponsiveness of human tumours and the initial slope of the cell survival curve. Radiother Oncol 1984;2:317-23.
13. Deschavanne PJ, Fertil B. A review of human cell radiosensitivity in vitro. Int J Radiat Oncol Biol Phys 1996;34(1):251-66.
14. Karlsson KH, Stenerlow B. Focus formation of DNA repair proteins in normal and repair-deficient cells irradiated with high-LET ions. Radiat Res 2004;161:517-27.
15. Johansson L, Nilsson K, Carlsson J, Larsson B, Jakobsson P. Radiation effects on cultured human lymphoid cells. Analysis using the growth extrapolation method. Acta Radiol Oncol 1981;20:51-9.
16. Persson MI, Gedda L, Jensen HJ, Lundqvist H, Malmstrom PU, Tolmachev V. Astatinated trastuzumab, a putative agent for radionuclide immunotherapy of ErbB2-expressing tumours. Oncol Rep 2006;15(3):673-80.
17. Wikman M, Steffen AC, Gunneriusson E, Tolmachev V, Adams GP, Carlsson J, et al. Selection and characterization of HER2/neu-binding affibody ligands. Protein Eng DeS Selection (PEDS) 2004;17(5):455-62.
18. Steffen AC, Wikman M, Tolmachev V, Adams GP, Nilsson F, Ståhl S, et al. In vitro characterization of a bivalent anti-HER2 affibody with potential for radionuclide based diagnostics. Cancer Biother Radiopharm 2005;20(3):239-48.
19. Steffen AC, Orlova A, Wikman M, Nilsson F, Ståhl S, Adams GP, et al. Affibody mediated tumour targeting of HER-2 expressing xenografts in mice. Eur J Nucl Med Mol Imaging 2006;33(6):631-8.
20. Orlova A, Magnusson M, Eriksson T, Nilsson M, Larsson B, Höiden-Guthenberg I, et al. Tumor imaging using a picomolar affinity HER-2 binding affibody molecule. Cancer Res 2006;66(8):4339-433.
21. Tolmachev V, Orlova A, Pehrson R, Galli J, Baastorp B, Andersson K, et al. Radionuclide therapy of HER2-positive micro-xenografts using a 177-Lu-labeled HER2-specific Affibody molecule. Cancer Res 2007;67(6):2773-82.
22. Hartman T. Tumour targeting with stable and radioactive nuclides: dosimetric aspects at the cellular level. Doctoral thesis, Uppsala University. Uppsala: Acta Universitatis Upsaliensis; 1999.
23. Palm S, Humm JL, Rundqvist R, Jacobsson L. Microdosimetry of astatine-211 single-cell irradiation: role of daughter polonium-211 diffusion. Med Phys 2004;31:218-25.
24. Palm S. In vitro effects and microdosimetry of astatine-211 for tumour therapy. Doctoral thesis, University of Göteborg, Sahlgrenska University Hospital (ISBN 91-628-3841-5); 1999.
25. Nordberg E, Friedman M, Göstring L, Adams GP, Brismar H, Nilsson FY, et al. Cellular studies of binding, internalization and retention of a radiolabeled EGFR-binding affibody molecule. Nucl Med Biol 2007;34(6):609-18.
26. Dikomey E, Brammer I. Relationship between cellular radiosensitivity and non-repaired double-strand breaks studied for different growth states, dose-rates and plating conditions in a normal human fibroblast line. Int J Radiat Biol 2000;76(6):773-81.
27. Yaginuma Y, Westphal H. Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. Cancer Res 1992;52:4196-9.
28. Carlsson J, Hakansson E, Eriksson V, Grawe J, Wester K, Grusell E, et al. Early effects of low dose-rate radiation on cultured tumor cells. Cancer Biother Radiopharm 2003b;18:663-70.
29. Lennartsson J, Carlsson J, Stenerlöw B. Targeting the epidermal growth factor receptor family in radionuclide therapy of tumors-signal transduction and DNA repair. Lett Drug Des Discov 2006;3:357-68.
30. Petru E, Sevin BU, Gottlieb C. Radiosensitivity patterns of four human ovarian cancer cell lines in vitro. Gynecol Oncol 1997;64:490-2.
31. Steren A, Sevin BU, Perras J, Angioli R, Nguyen H, Guerra L, et al. Taxol sensitizes human ovarian cancer cells to radiation. Gynecol Oncol 1993;48(2):252-8.
32. Joiner MC, Marples B, Lambin P, Short SC, Turesson I. Low-dose hypersensitivity: current status and possible mechanisms. Int J Radiat Oncol Biol Phys 2001;49(2):379-89.
33. Murray D, McEwan AJ. Radiobiology of systemic radiation therapy. Cancer Biother Radiopharm 2007;22(1):1-23.
34. Chapman JD. Single-hit mechanism of tumour cell killing by radiation. Int J Radiat Biol 2003;79:71-81.
35. Prise KM, Folkard M, Michael BD. A review of the bystander effect and its implications for low-dose exposure. Radiat Prot Dosim 2003;104(4):347-55.
36. Stenerlow B, Pettersson O, Essand M, Blomquist E, Carlsson J. Irregular variations in radiation sensitivity when the linear energy transfer is increased. Radiother Oncol 1995;36(2):133-42.
37. Ekerljung L, Steffen AC, Carlsson J, Lennartsson J. Effects of HER2-binding affibody molecules on intracellular signaling pathways. Tumour Biol 2006;27(4):201-10.
38. Zalutsky MR, Pozzi OR. Radioimmunotherapy with alpha-particle emitting radionuclides. Q J Nucl Med Mol Imaging 2004;48:289-96.
39. Smith-Jones PM, Solit DB, Akhurst T, Afroze F, Rosen N, Larson SM. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 2004;22(6):701-6.
40. Smith-Jones PM, Solit D, Afroze F, Rosen N, Larson SM. Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET. J Nucl Med 2006;47(5):793-6.